vs
Bone Biologics Corp（BBLG）与Rani Therapeutics Holdings, Inc.（RANI）财务数据对比。点击上方公司名可切换其他公司
Bone Biologics Corp是一家临床阶段生物技术企业，专注研发用于脊柱融合等骨科手术的骨再生修复生物制剂，主要面向美国医疗市场，核心业务覆盖骨科护理及再生医学领域。
Rani Therapeutics Holdings是一家临床阶段生物技术企业，专注于开发可替代注射类生物制剂的口服给药方案，核心专利技术RaniPill是一款机器人给药胶囊，可将大分子药物直接递送至肠壁，免除患者注射痛苦，针对糖尿病、自身免疫疾病、骨质疏松等慢性病患者，与多家头部药企合作推进产品管线。
BBLG vs RANI — 直观对比
营收规模更大
BBLG
是对方的Infinity倍
$0
损益表 — Q1 FY2024 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $255 | $0 |
| 净利润 | $-866.0K | $-5.4M |
| 毛利率 | — | — |
| 营业利润率 | -354327.8% | — |
| 净利率 | -339596.1% | — |
| 营收同比 | -54.1% | — |
| 净利润同比 | 76.7% | 20.2% |
| 每股收益（稀释后） | $-1.31 | $-0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBLGRANI
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $172.0K | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | $255 | $0 | ||
| Q4 23 | $348 | — | ||
| Q3 23 | $536 | — |
净利润BBLGRANI
| Q3 25 | — | $-5.4M | ||
| Q2 25 | — | $-6.7M | ||
| Q1 25 | — | $-7.3M | ||
| Q3 24 | — | $-6.8M | ||
| Q2 24 | — | $-6.8M | ||
| Q1 24 | $-866.0K | $-7.5M | ||
| Q4 23 | $-1.5M | — | ||
| Q3 23 | $-1.9M | — |
营业利润率BBLGRANI
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6984.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -354327.8% | — | ||
| Q4 23 | -333335.6% | — | ||
| Q3 23 | -388225.7% | — |
净利率BBLGRANI
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4223.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -339596.1% | — | ||
| Q4 23 | -445369.3% | — | ||
| Q3 23 | -358154.7% | — |
每股收益（稀释后）BBLGRANI
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-0.18 | ||
| Q1 25 | — | $-0.22 | ||
| Q3 24 | — | $-0.24 | ||
| Q2 24 | — | $-0.26 | ||
| Q1 24 | $-1.31 | $-0.29 | ||
| Q4 23 | $31.30 | — | ||
| Q3 23 | $-4.90 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $4.1M |
| 总债务越低越好 | — | $13.8M |
| 股东权益账面价值 | $3.7M | $-7.9M |
| 总资产 | $3.8M | $10.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BBLGRANI
| Q3 25 | — | $4.1M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $10.1M | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $4.5M | ||
| Q1 24 | — | $6.9M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
总债务BBLGRANI
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $21.3M | ||
| Q3 24 | — | $28.8M | ||
| Q2 24 | — | $30.0M | ||
| Q1 24 | — | $30.0M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
股东权益BBLGRANI
| Q3 25 | — | $-7.9M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | — | $-3.1M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $2.8M | ||
| Q1 24 | $3.7M | $7.4M | ||
| Q4 23 | $2.9M | — | ||
| Q3 23 | $3.8M | — |
总资产BBLGRANI
| Q3 25 | — | $10.1M | ||
| Q2 25 | — | $16.9M | ||
| Q1 25 | — | $24.1M | ||
| Q3 24 | — | $43.5M | ||
| Q2 24 | — | $43.7M | ||
| Q1 24 | $3.8M | $53.5M | ||
| Q4 23 | $3.7M | — | ||
| Q3 23 | $5.0M | — |
负债/权益比BBLGRANI
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 9.21× | ||
| Q2 24 | — | 10.58× | ||
| Q1 24 | — | 4.06× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-5.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BBLGRANI
| Q3 25 | — | $-5.1M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-8.1M | ||
| Q3 24 | — | $-8.4M | ||
| Q2 24 | — | $-9.0M | ||
| Q1 24 | $-1.3M | $-9.4M | ||
| Q4 23 | $-2.0M | — | ||
| Q3 23 | $-2.6M | — |
自由现金流BBLGRANI
| Q3 25 | — | — | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-8.2M | ||
| Q3 24 | — | $-8.5M | ||
| Q2 24 | — | $-9.1M | ||
| Q1 24 | — | $-9.4M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
自由现金流率BBLGRANI
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -4767.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
资本支出强度BBLGRANI
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 29.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
